The latest health and social care news and a look at research and development into the treatment of common and rare diseases alike. We also look at the vital changes being made to help deliver effective healthcare through the digital transformation within the NHS.
Steven T. Reed, O.D., President of the American Optometric Association, discusses age-related macular degeneration (AMD), the leading cause of severe vision loss in adults over 50, and the importance of early diagnosis and preventive care.
The number of people accessing talking therapies for conditions such as anxiety and depression via the NHS increased by 21.5% from 2020-21 to 2021-22, a new report shows.
Diabetic retinopathy is the real medical term for diabetic eye disease. It is the most common cause of blindness in people of working age. 94 million people are affected worldwide.
WHO Regional Office for Europe and the Ministry of Health and Care Services, Norway, reveal how making people’s access to medicines is a reality thanks to the Oslo Medicines Initiative.
The Long COVID lessons learned beyond the COVID-19 pandemic are detailed here by leading Professors working on the University College London STIMULATE-ICP programme.
Eric Buckland of Translational Imaging Innovations and Ronald Schuchard, Clinical Product Development Expert, explore the benefits of ophthalmic precision medicine to improve patient care across sectors.
Matthew Bradfield, Managing Director at Fairford Medical Ltd conducts a case study of Liverpool University Hospitals NHS Foundation Trust and its new CT scanner
In...
CEO of ViewMind Inc, Mark Edwards, discusses the cognitive effects of Long COVID, aiming to understand the science behind brain fog and other COVID symptoms.
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA and APAC at PTC Therapeutics explores how preparing Europe for a new generation of innovative therapies has the potential to transform the lives of patients.
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses different tuberculosis drug development regimens.
